R&D | April 15, 2026
Regeneron and Telix strike major radiopharma pact in push into next-gen cancer therapies
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The new capital is expected to fund the company through 2029
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
The therapy is mutation-agnostic and aims to overcome limitations of existing EGFR-targeting drugs by concentrating degradation in tumors while sparing healthy tissue
Harbour BioMed brings advanced antibody discovery platforms to the table
The move strengthens GBL’s clinical-stage presence in the United States
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
Experts will speak about primary tumours of the nervous system and also the tumours of other body parts which get metastasized to the nervous system
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
Subscribe To Our Newsletter & Stay Updated
